
Health care costs continue to rise, and hospitalization represents the single largest component of direct medical costs associated with cancer zzso zzso and its complications including zzso zzso zzso remain the major zzso toxicity of systemic cancer zzso The risk of zzso varies considerably across treatment regimens but appears to be significantly higher among elderly zzso The zzso factors zzso have been used effectively in a variety of clinical settings to prevent or treat zzso and to assist patients receiving zzso chemotherapy with or without stem cell zzso Several zzso controlled trials zzso have demonstrated the clinical efficacy of the zzso use of zzso A recently presented zzso of the available zzso has confirmed the efficacy of zzso zzso The cost of these agents, along with their large-scale clinical use, has prompted a number of economic zzso Economic models based on measures of resource zzso derived from zzso have provided zzso risk threshold estimates for the zzso use of zzso zzso A number of important studies concerning the clinical and economic impact of these agents in elderly cancer patients have been reported during the past zzso Continuing clinical and economic evaluation along with an updating of clinical practice guidelines especially related to elderly patients is recommended because of rapid zzso and clinical zzso 

